Next Article in Journal
Adjuvant Chemotherapy for Stage III Colon Cancer
Next Article in Special Issue
Oncological Results of Laparoscopically Assisted Radical Vaginal Hysterectomy in Early-Stage Cervical Cancer: Should We Really Abandon Minimally Invasive Surgery?
Previous Article in Journal
Evaluation of the Role of ITGBL1 in Ovarian Cancer
Previous Article in Special Issue
Results of a Phase I-II Study on Laser Therapy for Vaginal Side Effects after Radiotherapy for Cancer of Uterine Cervix or Endometrium
Review

Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research

Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, 56127 Pisa, Italy
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(9), 2678; https://doi.org/10.3390/cancers12092678
Received: 24 July 2020 / Revised: 4 September 2020 / Accepted: 16 September 2020 / Published: 19 September 2020
(This article belongs to the Special Issue Cervical Carcinoma)
The aim of this review is to assess the available literature of the pharmacological treatment of patients with metastatic, recurrent or persistent cervical cancer not amenable by surgery or radiotherapy. The results and toxicities of cisplatin-based doublets are exhaustively described. The combinations of cisplatin plus paclitaxel with or without bevacizumab is the most active regimen in these clinical setting. Immune-check-point inhibitors and molecularly-targeted agents are promising fields of research.
Cervical cancer patients with distant or loco-regional recurrences not amenable by surgery or radiotherapy have limited treatment options, and their 5-year overall survival (OS) rates range from 5% to 16%. The purpose of this paper is to assess the results obtained with chemotherapy and biological agents in this clinical setting. Several phase II trials of different cisplatin (CDDP)-based doublets and a phase III randomized trial showing a trend in response rate, progression-free survival, and OS in favor of CDDP + paclitaxel (PTX) compared with other CDDP-based doublets have been reviewed. The factors predictive of response to chemotherapy as well as the benefits and risks of the addition of bevacizumab to CDDP + PTX have been analyzed. The FDA has recently approved pembrolizumab for patients with recurrent or metastatic cervical cancer in progression on or after chemotherapy whose tumors were PD-L1 positive. Interesting perspectives of clinical research are represented by the use of immune checkpoint inhibitors alone or in addition to chemotherapy, whereas PARP inhibitors and PI3K inhibitors are still at the basic research phase, but promising. View Full-Text
Keywords: cervical cancer; chemotherapy; cisplatin; paclitaxel; bevacizumab; immune checkpoint inhibitors; phosphatidylinositol 3-kinase (PI3K) inhibitors; PARP inhibitors cervical cancer; chemotherapy; cisplatin; paclitaxel; bevacizumab; immune checkpoint inhibitors; phosphatidylinositol 3-kinase (PI3K) inhibitors; PARP inhibitors
MDPI and ACS Style

Gadducci, A.; Cosio, S. Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research. Cancers 2020, 12, 2678. https://doi.org/10.3390/cancers12092678

AMA Style

Gadducci A, Cosio S. Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research. Cancers. 2020; 12(9):2678. https://doi.org/10.3390/cancers12092678

Chicago/Turabian Style

Gadducci, Angiolo, and Stefania Cosio. 2020. "Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research" Cancers 12, no. 9: 2678. https://doi.org/10.3390/cancers12092678

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop